Privately-held startup PnuVax develops and manufactures vaccines and biopharmaceuticals that help address major public health threats on a worldwide scale. PnuVax joins worldwide efforts to eliminate preventable infectious diseases that take the lives of mothers and children.
Scientists from the University of Adelaide have made significant progress in the development of the first vaccine against the Zika virus. The team has successfully concluded its pre-clinical trials and is looking forward to Phase 1 of human clinical trials.
Zika is a “flavivirus” transmitted through mosquito bites that can infect pregnant women and cause congenital defects in the unborn child. Zika causes microcephaly, a congenital defect wherein the baby’s head is smaller than usual. Zika is also associated with other complications such as miscarriage, preterm birth, and neurologic conditions such as myelitis, neuropathy, and Guillain-Barre syndrome.
The researchers have found out that T-cell based vaccines can provide protection against systemic Zika infection. Pre-clinical trials conducted among mouse models have proven that a protective T-cell vaccine against Zika is achievable.
The success of this study has the potential to globally eradicate the Zika virus. Also, this study will serve as a reference for other research studies on flavivirus vaccines to shift focus on T-cell based vaccines.
Scientists from the University of Adelaide have made significant progress in the development of the first vaccine against the Zika virus. The team has successfully concluded its pre-clinical trials and is looking forward to Phase 1 of human clinical trials.
Zika is a “flavivirus” transmitted through mosquito bites that can infect pregnant women and cause congenital defects in the unborn child. Zika causes microcephaly, a congenital defect wherein the baby’s head is smaller than usual. Zika is also associated with other complications such as miscarriage, preterm birth, and neurologic conditions such as myelitis, neuropathy, and Guillain-Barre syndrome.
The researchers have found out that T-cell based vaccines can provide protection against systemic Zika infection. Pre-clinical trials conducted among mouse models have proven that a protective T-cell vaccine against Zika is achievable.
The success of this study has the potential to globally eradicate the Zika virus. Also, this study will serve as a reference for other research studies on flavivirus vaccines to shift focus on T-cell based vaccines.
